Ayahuasca and iboga are both plant medicines with long ceremonial histories. They are not alternatives to each other. They come from different continents, work through different neurological mechanisms, treat different things with different degrees of evidence, and cannot be used together safely. The question of ayahuasca and iboga — whether someone might pursue both — is less about choosing between them and more about understanding what each does and doesn't do, and whether sequencing them is ever appropriate.
In short: Iboga is a Central African root medicine active for 12–24 hours with strong evidence for opioid addiction interruption. Ayahuasca is a South American vine-and-leaf brew active for 4–6 hours with evidence primarily in depression and trauma. They cannot be combined simultaneously — the cardiac and serotonin syndrome risks are real. Sequential use, with appropriate intervals, is possible. Neither is appropriate for someone currently on SSRIs or SNRIs.
Where Each Medicine Comes From
Iboga (Tabernanthe iboga) is a shrub native to the rainforests of Gabon, Cameroon, and the Republic of Congo. Its root bark contains ibogaine — the primary psychoactive alkaloid — alongside other alkaloids that modify and extend the experience. The Bwiti people of Gabon and Cameroon have used iboga in initiation ceremonies for centuries. It is not recreational. It is a rite of passage, often lasting multiple nights, conducted within a specific spiritual and communal framework. The tradition is described in more detail in the post on the Bwiti spiritual tradition.
Ibogaine's history in the West starts differently. In the 1960s, a heroin user named Howard Lotsof took ibogaine recreationally and emerged 36 hours later without withdrawal symptoms and without craving. That observation launched decades of research, which the US interrupted by scheduling ibogaine in 1970. Research continued in Canada, Mexico, and the Netherlands.
Ayahuasca is a brew prepared by combining Banisteriopsis caapi vine with Psychotria viridis leaves or other DMT-containing plants. It comes from the Amazon basin and has been used by indigenous peoples of Peru, Brazil, Colombia, and Ecuador in healing and ceremonial contexts for thousands of years. Shipibo healers, Santo Daime practitioners, and the União do Vegetal are among the most documented traditions.
The caapi vine provides beta-carboline alkaloids that inhibit monoamine oxidase (MAO) enzymes. This makes DMT — the active molecule in the Psychotria leaves — orally active. Without the vine, DMT is broken down in the gut before it reaches the brain.
How Each Medicine Works
Ibogaine acts on multiple receptor systems simultaneously, which is part of why its effects are so unlike other psychedelics. It is an NMDA antagonist, a kappa-opioid agonist, and it interacts with serotonin and dopamine transporters. In people with opioid dependence, ibogaine appears to reset opioid receptors — reducing or eliminating withdrawal symptoms, suppressing craving, and producing a window of neurological flexibility during which new patterns are more possible. Its metabolite, noribogaine, remains active in the system for weeks after a single ceremony, continuing to modulate mood and craving.
The active experience lasts 12–24 hours. As described in the post on the ibogaine experience, it typically begins with a visionary phase — often described as a rapid, non-linear review of one's life — followed by a period of deep introspection and a slow return to waking consciousness. Recovery takes 2–3 days. This is not a weekend event.
Ayahuasca acts primarily through DMT, a serotonin agonist — specifically a potent 5-HT2A receptor agonist, the same receptor activated by psilocybin and LSD. The beta-carboline MAO inhibitors extend and intensify its effects by blocking the enzyme that would otherwise break down DMT quickly. The experience typically lasts 4–6 hours and tends to involve intense visual imagery, emotional processing, and purgative physical responses.
Here is where simultaneous use becomes dangerous: ayahuasca's beta-carbolines are MAO inhibitors. Ibogaine prolongs the QT interval on an EKG. Combining them means adding a serotonergic surge — from DMT — to a cardiovascular system under ibogaine's influence. The cardiac arrhythmia risk is real. There is no safe simultaneous combination. Any provider offering both medicines in the same ceremony is not operating safely.
What Each Is Used For
Ibogaine has the strongest clinical evidence for opioid use disorder. A 2023 study published in Nature Medicine followed 30 veterans who received ibogaine treatment at a clinic in Mexico — all had histories of traumatic brain injury, opioid use, and PTSD. One month after a single treatment: 88% reduction in PTSD symptoms, 87% reduction in depression, 81% reduction in anxiety. Those numbers are compelling enough to stand on their own with the methodological caveats included — 30 participants, no placebo arm, no long-term follow-up beyond one month at publication. Citing these numbers without the caveats is not honest. Citing the caveats as a reason to dismiss the findings is not honest either.
For PTSD and depression not connected to opioid dependence, the evidence for ibogaine is less developed than for ayahuasca. Multiple studies — from Imperial College London, MAPS, and others — have shown significant reductions in depression severity after ayahuasca ceremonies, including in people with treatment-resistant depression. The mechanism there is more psychotherapeutic and serotoninergic than the neurological reset ibogaine produces.
The evidence for ayahuasca in addiction is thinner than for ibogaine. Small studies have shown reductions in alcohol and cocaine use in ceremonial contexts, but the mechanism is different and the controlled trial data is not yet at the level of the opioid research for ibogaine. If opioid or stimulant dependence is the primary concern, ibogaine is the medicine the evidence points toward.
For a direct comparison of mechanism and use, the post on iboga vs. ayahuasca goes deeper on the pharmacological differences.
When Both Are Used — The Sequencing Question
Some people pursue iboga first and ayahuasca months or years later — not as a designed clinical protocol but as a continuation of their own integration process. This sequencing is not uncommon. Done with appropriate intervals and preparation, it is generally considered less risky than the reverse.
Iboga tends to produce what participants describe as a comprehensive biographical confrontation — analytical, often forensic, a review of one's history and patterns. Ayahuasca tends to be more relational, somatic, and for many people more emotionally immediate. Someone who has completed iboga work and processed the addiction dimension of their experience may later pursue ayahuasca to continue the emotional or spiritual dimension of integration.
The reverse sequence — ayahuasca first, then ibogaine — is more complicated. Ayahuasca's beta-carbolines are MAO inhibitors. The interaction between residual MAO inhibition and ibogaine's cardiac profile creates risk. A minimum of several months between ceremonies is generally recommended, and ideally with medical review beforehand confirming full metabolic clearance.
There is no standard protocol combining both. Providers offering ayahuasca-iboga sequences within the same retreat, or within weeks of each other, are creating risk without clinical justification. Anyone offering both in a single programme should be asked directly: what is the cardiac monitoring protocol, what is the interval between ceremonies, and what is the rationale for that interval. If they cannot answer all three questions specifically, that is a significant warning sign.
For context on how ibogaine is sometimes combined with a different medicine, the post on ibogaine and 5-MeO-DMT explains the Transcend approach.
Who Should Not Consider Either
The absolute contraindication shared by both medicines — the one most likely to affect people researching psychedelic therapy — is current SSRI or SNRI use. Ayahuasca's beta-carboline MAO inhibitors interact directly with serotonergic medications, with potentially fatal serotonin syndrome as the outcome. Ibogaine also carries serotonin syndrome risk via different pathways. Neither medicine has a safe “light dose” version that avoids this interaction. The required washout period depends on the specific medication. For fluoxetine (Prozac), which has an exceptionally long half-life, that period is measured in months, not weeks.
For ibogaine specifically: QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction; methadone without a supervised transition protocol; active psychosis or schizophrenia spectrum diagnosis; severe liver or kidney disease; lithium and certain other psychiatric medications; pregnancy.
For ayahuasca specifically: any medication metabolised by the CYP450 enzyme pathway, which MAO inhibitors disrupt; cardiovascular conditions that increase the risk of acute hypertension; active psychosis.
Someone in acute psychiatric crisis is not an appropriate candidate for either ceremony, regardless of how much they want access. The experience amplifies what is present. Entering it in a state of acute instability does not produce stability — and we say this directly when it applies, not after someone has already arrived.
Is This Right for You?
If opioid or stimulant dependence is the primary concern — eliminating withdrawal, resetting craving — ibogaine is the medicine with the stronger evidence base for that specific outcome. Ayahuasca is not a substitute here.
If the primary need is processing trauma, depression, or grief, and you are not on contraindicated medications and do not have cardiac contraindications, ayahuasca has a meaningful evidence base and is more globally accessible.
If you have completed iboga work and are considering ayahuasca as a continuation, that conversation starts with the provider who guided your iboga ceremony — they know what emerged and whether the timing makes sense.
What is not a good reason to pursue both: pursuing the second medicine because the first seemed insufficient, or because more seems like better. Neither medicine works like that. The integration period — the months of applying what emerged — is where the outcome is determined. Adding a second medicine before the first has been integrated is not an escalation of healing. It is a disruption of it.
If you are considering iboga ceremony at Transcend, the application starts here. Medical screening happens before any commitment is made.
Frequently Asked Questions
Are ayahuasca and iboga the same medicine?
No. They come from different continents, different plant families, and different cultural traditions. Iboga is from Central Africa and contains ibogaine as its primary alkaloid. Ayahuasca is from South America and contains DMT made orally active by MAO inhibitors from the caapi vine. Their neurological mechanisms are different, their durations are different (12–24 hours for iboga, 4–6 hours for ayahuasca), and the conditions they are best supported by evidence to address are different.
Can you take ayahuasca and iboga at the same time?
No. Ibogaine prolongs the QT interval on an EKG. Ayahuasca's beta-carboline alkaloids are MAO inhibitors that potentiate serotonergic activity. Combining them simultaneously creates compounded cardiac and serotonin syndrome risk. Any provider offering both medicines in the same ceremony is not operating safely.
Which medicine is better for opioid addiction?
Ibogaine has the stronger evidence base. A 2023 Nature Medicinestudy of 30 veterans showed 88% reduction in PTSD symptoms, 87% in depression, and 81% in anxiety at one month following a single ibogaine treatment. Ibogaine's mechanism — resetting opioid receptors and producing weeks of noribogaine activity — has a direct pharmacological rationale for addiction interruption. Ayahuasca's evidence in opioid addiction is limited; its more documented uses are in alcohol, cocaine, and depression.
Is iboga or ayahuasca more intense?
Iboga is active for 12–24 hours; ayahuasca for 4–6 hours. Duration is not the same as intensity. Iboga's extended duration produces a different kind of demand — longer and less relenting. Ayahuasca's shorter duration can produce extreme intensity within that window. They are not meaningfully comparable on a single scale. They are different in kind, not just degree.
Can you do ayahuasca after iboga?
Yes, with an appropriate interval. Most practitioners recommend a minimum of several months between iboga and any subsequent ayahuasca ceremony — primarily to allow full clearance of ibogaine's active metabolite noribogaine and to allow integration of what the iboga ceremony produced. Iboga first, then ayahuasca later, is considered less risky than the reverse. It is not a designed protocol — it reflects how some people naturally progress in their own work.
Does ayahuasca work for opioid addiction?
The evidence for ayahuasca in opioid addiction is limited. Existing studies focus primarily on alcohol and cocaine, not opioids. The mechanism — 5-HT2A receptor modulation and psychotherapeutic processing — does not include the opioid receptor reset that ibogaine produces. For someone whose primary concern is opioid dependence, ayahuasca is not the medicine the evidence points toward.
Do ayahuasca and ibogaine have the same contraindications?
They share the most important one: SSRIs and SNRIs are absolute contraindications for both. Both medicines interact dangerously with serotonergic medications. They differ on cardiac risk: ibogaine's QT prolongation requires EKG screening before any ceremony — a contraindication specific to ibogaine. Ayahuasca's MAOI profile creates additional drug interactions that ibogaine does not share. Anyone on multiple medications should have both lists reviewed by a physician familiar with both medicines.
How do I know which medicine is right for me?
Start with the primary goal. Opioid or stimulant dependence points toward ibogaine. Trauma, depression, or grief processing without dependence is where ayahuasca has the more developed evidence base. Both require medical screening and a period of preparation and integration. Neither is appropriate for someone currently on SSRIs or SNRIs. If you are considering iboga ceremony, the application process at Transcend includes medical screening before any commitment is made.
Sources
MAPS — Ibogaine research overview
Nunes et al. (2019). Ayahuasca and current psychiatric medications. Frontiers in Pharmacology.